Dose-Dense MVAC With Pegfilgrastim Support in Subjects With Muscle-Invasive Urothelial Carcinoma
Status:
Completed
Trial end date:
2016-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to test the effectiveness of neoadjuvant dose-dense
methotrexate, vinblastine, doxorubicin, and cisplatin (ddMVAC) in combination with
pegfilgrastim followed by radical surgery in patients with muscle-invasive urothelial
carcinoma.
Phase:
Phase 2
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborators:
Amgen Beth Israel Deaconess Medical Center Brigham and Women's Hospital